Vertex PharmaceuticalsWBO:VRTX +2.51%90 Median PS Value is €476.63 as of Jun. 24, 2026, which is 100% below its 10-year median of 0.73. GuruFocus rates WBO:VRTX with a GF Score™ of 90/100 and a GF Value™ of €439.78 (Fairly Valued). The stock has 4 warning signs investors should review. Among 276 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 67.39% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Vertex Pharmaceuticals's Median PS Value or its related term are showing as below:
WBO:VRTX'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45 Med: 0.73 Max: 0.95
Current: 0.86
During the past 13 years, the highest Price to Median PS Value of Vertex Pharmaceuticals was 0.95. The lowest was 0.45. And the median was 0.73.
WBO:VRTX's Price-to-Median-PS-Value is ranked worse than 67.39% of 276
companies
in the Biotechnology industry
Industry Median: 0.63
vs WBO:VRTX: 0.86
Vertex Pharmaceuticals (WBO:VRTX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Vertex Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
410.10
/
476.63
=
0.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals Median PS Value Related Terms
Vertex Pharmaceuticals Median PS Value Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VRTX vs REGN, ALNY, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 11.6772.
Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €40.817.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (WBO:VRTX) has a Median PS Value of €476.63 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Vertex Pharmaceuticals and its competitors. This is 65192% above median its historical median of 0.73. Over the past decade, Vertex Pharmaceuticals' Median PS Value has ranged from 0.45 to 0.95. According to the industry distribution chart, Vertex Pharmaceuticals ranks #186 out of 276 companies in the Biotechnology industry, placing it in the top 67.4%.
Is Vertex Pharmaceuticals' Median PS Value too high?
Vertex Pharmaceuticals' current Median PS Value of €476.63 is 65192% above median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 0.95. Based on the distribution chart, Vertex Pharmaceuticals ranks #186 out of 276 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Median PS Value compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #186 out of 276 companies for Median PS Value. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median Median PS Value is 0.63. Historically, Vertex Pharmaceuticals' own Median PS Value has ranged from 0.45 to 0.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Median PS Value is €476.63, which is 65192% above median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €439.78, compared to a current price of €410.10 — trading 6.7% below its estimated fair value. The current Median PS Value is €476.63, which is 65192% above median its 10-year median of 0.73. Vertex Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Median PS Value is €476.63 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of €410.10 is trading 6.7% below its estimated GF Value™ of €439.78.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for WBO:VRTX:
Median PS Value: €476.63 (65192% above median its 10-year median of 0.73)
GF Value™: €439.78 vs. price of €410.10 (6.7% below fair value)
No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
90GF Score
Get the complete analysis for WBO:VRTX
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VRTX has been successfully added to your 
